Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization...

JAGX : 2.70 (+2.66%)
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications

FLHLF : 0.0200 (+0.50%)
JAGX : 2.70 (+2.66%)
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus...

JAGX : 2.70 (+2.66%)
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value

JAGX : 2.70 (+2.66%)
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs

JAGX : 2.70 (+2.66%)
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing

JAGX : 2.70 (+2.66%)
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately...

JAGX : 2.70 (+2.66%)
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Click here to register

JAGX : 2.70 (+2.66%)
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer...

JAGX : 2.70 (+2.66%)
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series

Click here to register

JAGX : 2.70 (+2.66%)

Barchart Exclusives

Tariffs, Inflation and Other Key Things to Watch this Week
Markets enter the heart of earnings season with the S&P 500 facing a critical test as major financial institutions kick off quarterly results amid escalating trade tensions. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar